ENSAYO CLÍNICO, ABIERTO, DE GRUPOS PARALELOS, FASE III, PARA VALORAR EL EFECTO ANTIPROTEINÚRICO DE LOS DERIVADOS DE LA VITAMINA D EN PACIENTES CON ENFERMEDAD RENAL CRÓNICA E INSUFICIENCIA DE VITAMINA D.
- Conditions
- Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]MedDRA version: 14.0Level: SOCClassification code 10038359Term: Renal and urinary disordersSystem Organ Class: 10038359 - Renal and urinary disorders
- Registration Number
- EUCTR2010-024023-25-ES
- Lead Sponsor
- orenzo Victor, PhD
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 174
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 174
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does Nefrovid2010 (EUCTR2010-024023-25-ES) investigate antiproteinuric mechanisms of vitamin D derivatives in CKD?
What is the comparative effectiveness of vitamin D derivatives vs. standard-of-care therapies for proteinuria in CKD patients?
Which biomarkers correlate with response to vitamin D derivative therapy in EUCTR2010-024023-25-ES CKD trial?
What adverse events are associated with vitamin D derivatives in CKD management, and how are they mitigated?
Are there synergistic combination strategies involving vitamin D analogs and renin-angiotensin system inhibitors for CKD treatment?